Biohaven Pharmaceuticals to be acquired by Pfizer
The $11.6 billion agreement will see Pfizer acquire Biohaven’s calcitonin gene-related peptide programmes, including migraine treatment rimegepant.
Source: europeanpharmaceuticalreview.com
Pfizer Internal News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pfizer Internal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pfizer Internal Today - Breaking & Trending Today
Pfizer snaps up migraine drugmaker Biohaven for $11.6bn
Acquiring Biohaven is Pfizer’s biggest deal in years and will allow the company to commercialise the Nurtec medication for migraine attacks.
Source: siliconrepublic.com
Pfizer to Acquire Biohaven Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and ...
Source: pharmiweb.com
Pfizer Drops a Cool $11.6B on Migraine Leader Biohaven
Pfizer made the splash of the young week Tuesday morning, inking an acquisition deal with New Haven, Connecticut-based Biohaven Pharma totaling $11.6 billion.
Source: biospace.com
Pfizer Inc.: Pfizer and Biohaven's VYDURA (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA (rimegepant), a
Source: finanznachrichten.de